Levodopa (L‐dopa) remains the basis of pharmacological treatment of Parkinson's disease (PD). However, L‐dopa therapy is associated with the development of complications and presents major challenges in the long‐term treatment. Thus, other medications may be suggested to delay and/or reduce the doses of L‐dopa in order to prevent complications. The interpretation of treatment evolution reported in clinical trials on PD may be tricky, especially due to some variability in medications and dose regimens. Some authors have suggested a conversion factor to generate a total L‐dopa equivalent daily dose (LEDD), calculated as a sum of each parkinsonian medication. Therefore, LEDD provides an artificial summary of the total daily medication a patient is receiving, and to date, there is no report focusing on the clinical interpretation of this parameter. Thus, based on a 3‐year, multi‐center retrospective study assessing the impact of second‐line therapy initiation on LEDD in PD patients, the aim of our article was to discuss LEDD as a quantitative outcome to estimate the impact of second‐line therapies on medication regimens; and in the second part of the discussion, to provide a narrative review of the clinical outcomes associated with LEDD in the literature.

No abstract